Jushi Holdings (JUSHF) Non Operating Income (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Non Operating Income came in at -$12.7 million in Q1 2026, down 106.18% year-on-year from $205.7 million in Q1 2025, and down 39.93% on a QoQ basis from -$9.1 million in Q4 2025.
Jushi Holdings (JUSHF) Non Operating Income (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Non Operating Income data on file, last reported at -$12.7 million in Q1 2026.
- On a quarterly basis, Non Operating Income fell 106.18% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$45.0 million, a 82.69% decrease from a year earlier, with the FY2025 full-year figure at -$38.5 million, down 37.29% from the prior year.
- Non Operating Income for Q1 2026 stood at -$12.7 million, down from -$9.1 million in the prior quarter.
- Over the last five years, Non Operating Income for JUSHF reached as high as $31.9 million in Q2 2022 and fell as low as -$17.2 million in Q3 2025.
- Historically, Non Operating Income has averaged -$5.3 million across 5 years, with a median of -$9.1 million in 2024.
- Across the five-year window, Non Operating Income soared 131.78% in 2022 and slumped 69784.62% in 2025, its largest moves.
- Year by year, Non Operating Income stood at -$11.4 million in 2022, then jumped by 75.27% to -$2.8 million in 2023, then surged by 99.54% to -$13000.0 in 2024, then slumped by 69784.62% to -$9.1 million in 2025, then tumbled by 39.93% to -$12.7 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$12.7 million in Q1 2026, -$9.1 million in Q4 2025, and -$17.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | -12.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.71 Mn |
| Dec 31, 2025 | -9.09 Mn |
| Sep 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -6.01 Mn |
| Mar 31, 2025 | -6.17 Mn |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | -9.38 Mn |
| Jun 30, 2024 | -9.07 Mn |
| Mar 31, 2024 | -9.54 Mn |
| Dec 31, 2023 | -2.82 Mn |
| Sep 30, 2023 | -15.44 Mn |
| Jun 30, 2023 | -9.79 Mn |
| Mar 31, 2023 | 219,000.00 |
| Dec 31, 2022 | -11.42 Mn |
| Sep 30, 2022 | -7.05 Mn |
| Jun 30, 2022 | 31.85 Mn |
| Mar 31, 2022 | 3.49 Mn |
| Dec 31, 2021 | 40.86 Mn |
| Sep 30, 2021 | 47.84 Mn |
| Jun 30, 2021 | 13.74 Mn |